Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

导出原文传递

翻译打印收藏纠错

第一作者： Anthony S,Stein

第一单位： Gehr Family Center for Leukemia Research, City of Hope, Duarte, California. Electronic address: astein@coh.org.

作者： Anthony S,Stein ^[1] ; Hagop,Kantarjian ^[2] ; Nicola,Gökbuget ^[3] ; Ralf,Bargou ^[4] ; Mark R,Litzow ^[5] ; Alessandro,Rambaldi ^[6] ; Josep-Maria,Ribera ^[7] ; Alicia,Zhang ^[8] ; Zachary,Zimmerman ^[8] ; Gerhard,Zugmaier ^[9] ; Max S,Topp ^[10]

作者单位： Gehr Family Center for Leukemia Research, City of Hope, Duarte, California. Electronic address: astein@coh.org. ^[1] The University of Texas M.D. Anderson Cancer Center, Houston, Texas. ^[2] Department of Medicine II, Goethe University, Frankfurt, Germany. ^[3] Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany. ^[4] Mayo Clinic, Rochester, Minnesota. ^[5] Department of Oncology and Hemato-Oncology, University of Milan and Azienda Pope John XXIII Hospital, Bergamo, Italy. ^[6] Catalan Institute of Oncology-Hospital Germans Trias i Pujol, Jose Carreras Leukemia Research Institute, Badalona, Spain. ^[7] Amgen Inc, Thousand Oaks, California. ^[8] Amgen Research Munich, Munich, Germany. ^[9] Medical Clinic and Polyclinic II, University Hospital Würzburg, Würzburg, Germany. ^[10]

关键词 Allogeneic hematopoietic stem cell transplantation Blinatumomab Efficacy Philadelphia chromosome-negative B precursor ALL Safety